Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
23 05 2023
23 05 2023
Historique:
accepted:
14
10
2022
received:
25
04
2022
medline:
12
5
2023
pubmed:
10
11
2022
entrez:
9
11
2022
Statut:
ppublish
Résumé
Subsequent neoplasms (SNs) compromise long-term survivors after hematopoietic cell transplantation. We performed a retrospective analysis of SNs in 10 358 recipients of umbilical cord blood transplantation (UCBT) from 1988 to 2018. SNs developed in 233 patients and 84 were of pediatric age. Indications for UCBT were malignant hematological diseases in 199 patients (85%). Three groups of SNs were observed. Posttransplant lymphoproliferative disorders (PTLD) were reported in 145 patients in a median of 4 months after UCBT. Of these, 9 patients died from relapse, 83 from PTLD, and 24 from transplant-related causes. At last follow-up, 29 were alive; 5-year overall survival (OS) after PTLD diagnosis was 21%. Acute leukemia/myelodysplasia (AL/MDS) was diagnosed in 23 patients in a median of 28 months after UCBT and included 3 donor-cell AL. Four of 23 patients died from relapse of primary disease, 8 from progression of SNs, and 4 from TRM. Seven patients remain alive; the 5-year OS after AL/MDS diagnosis was 36%. Solid tumors (ST) were reported in 65 patients in a median of 54 months after UCBT. Most common tumor sites were lung, thyroid, bone, and soft tissue. A total of 33 patients died (26 owing to ST, 6 to relapse of primary disease, and 1 cause missing). At last follow-up, 32 of 65 patients were alive; the 5-year OS after the diagnosis of ST was 51%. In conclusion, despite their poor outcomes, SNs that occur after UCBT are extremely rare. Identification of risk factors and early detection may help to improve OS.
Identifiants
pubmed: 36350759
pii: 487051
doi: 10.1182/bloodadvances.2022007941
pmc: PMC10189403
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1976-1986Informations de copyright
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Blood. 2007 Oct 15;110(8):3064-70
pubmed: 17569820
Blood. 2005 Dec 15;106(13):4377-80
pubmed: 16118319
Blood. 2007 Apr 1;109(7):2688-92
pubmed: 17132724
Bone Marrow Transplant. 2016 Jan;51(1):83-8
pubmed: 26367222
Bone Marrow Transplant. 2008 Aug;42(3):181-6
pubmed: 18516079
Biol Blood Marrow Transplant. 2006 May;12(5):491-505
pubmed: 16635784
Blood. 2006 Oct 15;108(8):2874-80
pubmed: 16804113
J Clin Oncol. 2009 Jul 10;27(20):3354-62
pubmed: 19451438
Biol Blood Marrow Transplant. 2007 Jan;13(1):82-9
pubmed: 17222756
Leukemia. 2006 Apr;20(4):744-5
pubmed: 16437136
Haematologica. 2016 Jul;101(7):803-11
pubmed: 27365460
Curr Probl Dermatol. 2012;43:132-49
pubmed: 22377926
Haematologica. 2005 Jul;90(7):969-75
pubmed: 15996934
Blood. 2007 Apr 1;109(7):2794-6
pubmed: 17110459
Blood. 2007 Feb 1;109(3):1322-30
pubmed: 17038536
Bone Marrow Transplant. 2009 Feb;43(4):315-21
pubmed: 18836488
Blood. 2009 Jan 29;113(5):1175-83
pubmed: 18971419
Blood. 2009 May 14;113(20):4992-5001
pubmed: 19264919
J Clin Oncol. 1999 Oct;17(10):3122-7
pubmed: 10506608
J Clin Oncol. 2003 Apr 1;21(7):1352-8
pubmed: 12663726
Blood. 1999 Oct 1;94(7):2208-16
pubmed: 10498590
Bone Marrow Transplant. 2015 Aug;50(8):1013-23
pubmed: 25822223
Leukemia. 2013 Apr;27(4):829-35
pubmed: 23072778
Hematology Am Soc Hematol Educ Program. 2008;:142-9
pubmed: 19074072
Bone Marrow Transplant. 2005 Jul;36(2):115-21
pubmed: 15908969
Bone Marrow Transplant. 2008 Nov;42(9):631-3
pubmed: 18695662
Cancer Biol Ther. 2013 Dec;14(12):1077-88
pubmed: 24025414
Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91
pubmed: 19835968
Biol Blood Marrow Transplant. 2010 Jul;16(7):1025-31
pubmed: 20178854
Ann Oncol. 2014 Feb;25(2):435-41
pubmed: 24399081
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Biol Blood Marrow Transplant. 2007 May;13(5):505-16
pubmed: 17448909
Int J Hematol. 2012 Sep;96(3):342-9
pubmed: 22825970
Bone Marrow Transplant. 2012 Feb;47(2):251-7
pubmed: 21441959
Bone Marrow Transplant. 2014 Mar;49(3):397-402
pubmed: 24292521
Bone Marrow Transplant. 2017 Jul;52(7):969-976
pubmed: 28368379
Biol Blood Marrow Transplant. 2006 May;12(5):511-7
pubmed: 16635786
Haematologica. 2014 Feb;99(2):346-52
pubmed: 24056821
J Clin Oncol. 2012 Oct 20;30(30):3746-51
pubmed: 23008296
World J Transplant. 2020 Feb 28;10(2):29-46
pubmed: 32226769
Cancer. 2007 Jan 1;109(1):84-92
pubmed: 17131350
Vaccines (Basel). 2021 Mar 19;9(3):
pubmed: 33808928
Bone Marrow Transplant. 2009 Mar;43(5):429-31
pubmed: 18978827
Bone Marrow Transplant. 2009 Aug;44(4):265-6
pubmed: 19234516
Bone Marrow Transplant. 2002 Jun;29(12):999-1003
pubmed: 12098070
Leukemia. 2019 Feb;33(2):508-517
pubmed: 30050122
Curr Treat Options Oncol. 2018 Feb 8;19(2):9
pubmed: 29423555
Biol Blood Marrow Transplant. 2002;8(1):9-16
pubmed: 11846355
Bone Marrow Transplant. 2013 Feb;48(2):253-6
pubmed: 22773124
Clin Infect Dis. 2013 Sep;57(6):794-802
pubmed: 23771985
Biol Blood Marrow Transplant. 2007 Oct;13(10):1121-34
pubmed: 17889348
J Clin Oncol. 2013 Jan 1;31(1):39-48
pubmed: 23169501
Expert Rev Hematol. 2011 Aug;4(4):437-52; quiz 453-4
pubmed: 21801135
Blood. 2014 Oct 16;124(16):2514-22
pubmed: 25185261
Br J Haematol. 2011 Aug;154(3):301-10
pubmed: 21615719
Bone Marrow Transplant. 2014 Jan;49(1):102-9
pubmed: 24013690
Blood. 2011 Jan 6;117(1):316-22
pubmed: 20926773
Biol Blood Marrow Transplant. 2014 Nov;20(11):1777-84
pubmed: 25042734
Am J Surg Pathol. 2006 Mar;30(3):328-36
pubmed: 16538052
JAMA Oncol. 2019 Feb 1;5(2):229-235
pubmed: 30476975
Biol Blood Marrow Transplant. 2011 Jun;17(6):771-89
pubmed: 20951819
Leukemia. 2006 Sep;20(9):1633-4
pubmed: 16791267
Bone Marrow Transplant. 2020 Jun;55(6):1114-1125
pubmed: 31996792